Argitalpenak (86) Edel del Barco Morillo argitalpenak

2024

  1. COMPLICATIONS SECONDARY TO THE USE OF SGLT2 INHIBITORS IN ONCOLOGICAL PATIENTS: A SERIES OF 5 CASES

    European Journal of Case Reports in Internal Medicine, Vol. 11, Núm. 1

  2. Cancer-Associated Thrombotic Microangiopathy: Literature Review and Report of Five Cases

    Life, Vol. 14, Núm. 7

  3. Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients

    Archivos de Bronconeumologia, Vol. 60, Núm. 2, pp. 88-94

  4. Cuidados continuos en Oncología (I): generalidades

    Oncología clínica (Arán), pp. 147-155

  5. Cuidados continuos en oncología (II): control de los principales síntomas y del dolor, cuidados en el final de la vida, duelo

    Oncología clínica (Arán), pp. 157-173

  6. Cuidados continuos en oncología (III): infecciones en el paciente con cáncer, neutropenia febril

    Oncología clínica (Arán), pp. 175-188

  7. Cáncer de cabeza y cuello

    Oncología clínica (Arán), pp. 259-271

  8. Cáncer de pulmón

    Oncología clínica (Arán), pp. 227-257

  9. Diagnóstico nosológico y de extensión. Factores pronósticos

    Oncología clínica (Arán), pp. 59-71

  10. Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary Cancer

    International Journal of Molecular Sciences, Vol. 25, Núm. 4

  11. Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk

    Lung Cancer, Vol. 195

  12. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1647-1663

  13. Oncología clínica koord.

    Arán

2023

  1. Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study

    ERJ Open Research, Vol. 9, Núm. 6

  2. Biomarkers for immunotherapy in non-small cell lung cancer: a current and future reality

    Precision Cancer Medicine

  3. Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data

    Cancers, Vol. 15, Núm. 17

  4. Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis

    Chinese Clinical Oncology, Vol. 12, Núm. 6

  5. Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study

    Translational Lung Cancer Research, Vol. 12, Núm. 10, pp. 2113-2128

  6. TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck

    Frontiers in Oncology, Vol. 13

  7. The Impact of Liquid Biopsies Positive for EGFR Mutations on Overall Survival in Non-Small Cell Lung Cancer Patients

    Diagnostics, Vol. 13, Núm. 14